You just read:

First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combination with chemotherapy in first-line gastric adenocarcinoma and gastro-esophageal junction adenocarcinoma

News provided by

CStone Pharmaceuticals

Apr 16, 2019, 04:50 ET